External anogenital condylomas;Condylomes externes

Annales de Dermatologie et de Venereologie

Volumn 129, Issue 8-9, 2002, Pages 1013-1022

  Bouscarat, F ^a   Mahe E ^a   Descamps, V ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; WARTEC;

ARTICLE; CONDYLOMA; CRYOTHERAPY; DERMATITIS; ELECTROSURGERY; EXCISION; HUMAN; IMMUNE DEFICIENCY; LASER; MUCOSA; SEXUALLY TRANSMITTED DISEASE; VIRUS INFECTION; VIRUS LATENCY; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANTIVIRAL AGENTS; CAUSTICS; CONDYLOMATA ACUMINATA; CRYOSURGERY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON INDUCERS; INTERFERONS; KERATOLYTIC AGENTS; LASER SURGERY; MALE; PODOPHYLLIN; PODOPHYLLOTOXIN; SEXUAL PARTNERS; TRICHLOROACETIC ACID;

EID: 0036669236     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Laurent R. Infections génitales à papillomavirus. Rev Prat 1996;46:1961-8.
2. Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K et al. Sexual behaviour in Britain: Reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 2001;358:1851-4.
3. Koutsky LA et al. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
4. Becker TM, Stone KM, Alexander ER. Genital human papillomavirus infection. A growing concern. Obstet Gynecol Clin North Am 1987;14:389-96.
5. Simms I, Fairley CK. Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 1997;73:365-7.
6. Ferenczy A. Epidemiology and clinical pathophysiology of condylomata acuminata. Am J Obstet Gynecol 1995;172:1331-9.
7. Favre M, Ramoz N, Orth G. Human papillomaviruses: General features. Clin Dermatol 1997;15:181-98.
8. Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: Report of the American Medical Association consensus conference. Clin Infect Dis 1998;27:796-806.
9. Clinical effectiveness group. National guideline for the management of anogenital warts. Sex Transm Infect 1999;75(Suppl1):S71-5.
10. Von Krogh G, Lacey CJN, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000;76:162-8.
11. 1998 Guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998;47(RR-1):1-111.
12. nd Ed. New York, Mc Graw Hill, 1990;433.
13. Rice PS, Cason J, Best JM, Banatvala JE. High risk genital papillomavirus infections are spread vertically. Rev Med Virol 1999;9:15-21.
14. Tseng CJ, Liang CC, Soong YK, Pao CC. Perinatal transmission of human papillomavirus in infants: Relationship between infection rate and mode of delivery. Obstet Gynecol 1998;91:92-6.
15. Obalek S, Jablonska S, Favre M, WalczackL, Orth G. Condyloma acuminata in children: Frequent association with human papillomavirus responsible for cutaneous warts. J Am Acad Dermatol 1990;23:205-13.
16. Handley J, Hanks E, Armstrong K, Bingahm A, Dinsmore W, Swann A et al. Common association of HPV2 with anogenital warts in prepubertal children. Pediatr Dermatol 1997;14:339-43.
17. Aynaud O, Casanova JM, Barasso R. Penile intraepithelial neoplasia: Specific clinical features correlates with histologic and virologic findings. Cancer 1994;74:1762.
18. Aynaud O, Piron D, Barasso R, Poveda JD. Comparisons of clinical, histological, and virological symptoms of HPV in HIV-1 infected men and immunocompetent subjects. Sex Transm Infect 1998;74:32-4.
19. Wilson J EADV 2001.
20. Sobhani I, Vuagnat A, Walker F et al. Prevalence of high-grade dysplasia and cancer in the anal in human papillomavirus-infected individuals. Gastroenterology 2001;120:857-66.
21. Mahé E, Descamps V, Bouscarat F, Crickx B. Prise en charge des condylomes ano-génitaux externes par les dermatologues: Résultats d'une enquête nationale. Ann Dermatol Venereol 2002;29:997-1002.
22. Soler C, Chardonnet Y, Allibert P, Euvrard S, Schmitt D, Mandrand B. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol 1993;101:286-91.
23. Euvrard S, Kanitakis J, Chardonnet Y, Noble CP, Touraine JL, Faure M, Thivolet J, Claudy A. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997;133:175-8.
24. Kiviat N, Rompalo AA, Bowden R, Galloway D, Holmes KK, Corey L et al. Anal human papillomavirus among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990;162:358-61.
25. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immune Immune Defic Syndr 1994;7:599.606.
26. Williams AB, Darragh TM, Vranizan K, Ochia, Moss A, Palefsky JM. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelium abnormalities in human immunodeficiency virus infected women.Obstet Gynecol 1994;83:205-11.
27. Breese PL, Judson FN, Penley KA, Douglas JM. Anal human papillomavirus infection among homosexual and bisexual men: Prevalence of type specific infection and association with human immunodeficiency virus. Sex Transm Dis 1995;22:7-14.
28. Bouscarat F, Walker F, Crémieux AC, Grossin M, Coulaud JP, Carbon C, Belaich S. Lésions péniennes induites par les papillomavirus chez l'homme infecté ou non par le VIH: Étude prospective de 78 patients. Ann Dermatol Venereol 1998;125(s3):115.
29. Greenspan D, Canchola AJ, Mac Phail LA, Cheikh B, Greenspan JS. Effect of highly antiretroviral therapy on frequency of oral warts. Lancet 2001;357:1411-2.
30. Rotteleur G, Brunetaud JM, Martin G. Risque infectieux et laser CO2. Ann Dermatol Venereol 1998;125:341-2.
31. Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990;12:s620-32.
32. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
33. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Self-administered topical 5 p. 100 imiquimod cream for external anogenital warts. HPV Study Group. Human Papillomavirus. Arch Dermatol. 1998;134:25-30.
34. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
35. Garland SM, Sellors W, Wikstrom A, Petersen CS, Aranda C, Aractingi S, Maw RD. Imiquimod 5p. 100 is a safe and effecticve self applied treatment for anogenital warts: Results of an open-label, multicentre Phase IIIB trial. lint J STD Aids 2001;12:722-9.
36. Vexiau-Robert D, Decuypere L, Aractingi S. Efficaité et tolérance de l'imiquimod crème 5 p. 100 dans le traitement des condylomes acuminés externes: Résultats d'un suivi à 6 mois. Ann Dermatol Venereol 2001;128:3S188.
37. Snoeck R, van Ranst M, Andrei G, De Clerq E, De Wit S, Poncin M, Clumeck N. Treatment of anogenital papillomavirus infections with an acyclic nucleosie phosphonate analogue. N Engl J Med 1995;333:943-4.
38. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, van Ranst M et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33:597-602.
39. Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng FY et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000;18:1051-8.